phrykt

Endovia Health Sciences, Inc. (EDVA): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of EDVA were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No EDVA insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

EDVA short interest

Moderate short interest. 5.0% of EDVA shares are sold short: about 1 share in 20. Over the last 5 reports the number of shares short went up 41%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 321,101 EDVA shares were sold short, 5.0% of the shares outstanding, up 51.3% from the report before. At the average daily volume of 598,840 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

5.01%Aug 31Oct 305.68%

Days to cover

1.0Aug 31Oct 301.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026321,1015.01%+51%598,8401.0
Oct 15, 2026212,2373.31%+22%1.14M1.0
Sep 30, 2026173,9032.71%-49%11.99M1.0
Sep 15, 2026339,3215.29%+49%220,4901.5
Aug 31, 2026228,3513.56%-51%768,4241.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Endovia Health Sciences company events

Endovia Health Sciences filed 45 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership, listing). The latest was on Oct 27, 2026.

  1. Oct 27, 2026AgreementEndovia Health Sciences, a Nevada corporation entered into an Addendum to that certain Securities Purchase Agreement dated September 19, 2025 providing for an equity line of credit facility with C/M Capital Master Fund, LP, pursuant to which parties agreed to amend and supplement the ELOC Agreement… Filing
  2. Oct 15, 2026AgreementEndovia Health Sciences, a Nevada corporation entered into a letter agreement with C/M Capital Master Fund, LP pursuant to which parties agreed to amend that certain Securities Purchase Agreement dated September 19, 2025 entered into between the parties establishing an equity line of credit… Filing
  3. Oct 6, 2026SharesSold new shares outside a public offering. Filing
  4. Oct 5, 2026AnnouncementShared information with investors. Filing
  5. Sep 24, 2026AgreementEndovia Health Sciences, a Nevada corporation entered into an agreement with C/M Capital Master Fund, LP pursuant to which the Investor as a counterparty to that certain Exclusive License Agreement dated July 2, 2026, as amended, committed to invest a minimum of $1 million in the Company to support… Filing
  6. Sep 22, 2026AnnouncementShared information with investors. Filing
  7. Aug 31, 2026AnnouncementShared information with investors. Filing
  8. Aug 28, 2026SharesSold new shares outside a public offering. Filing
  9. Aug 26, 2026AgreementEndovia Health Sciences, Inc. entered into an Employment Agreement (each, an “Agreement”) with each of Brady Cobb for his employment as Interim Chief Executive Officer of the Company and Michael Bondurant for his employment as Interim Chief Operating Officer of the Company. Filing
  10. Aug 25, 2026AnnouncementShared information with investors. Filing
  11. Aug 21, 2026AnnouncementShared information with investors. Filing
  12. Aug 20, 2026ResultsReleased financial results. Filing
  13. Aug 12, 2026AnnouncementShared information with investors. Filing
  14. Aug 11, 2026RulesChanged its bylaws or articles. Filing
  15. Aug 5, 2026AnnouncementShared information with investors. Filing
  16. Aug 4, 2026AgreementSplash Beverage Group, Inc. entered into a Development and Collaboration Agreement with Lupvindol Biosciences Ltd., pursuant to which Lupvindol has agreed to lead the development of, and all U.S. Food and Drug Administration regulatory activities for, a new animal drug to be developed from the… Filing
  17. Jul 30, 2026AgreementAmended an earlier report. Splash Beverage Group, Inc. and Argent BioPharma Limited (ASX/LSE: RGT) entered into an addendum to that certain exclusive global license agreement for CannEpil®, dated July 6, 2026. Filing
  18. Jul 29, 2026AgreementSplash Beverage Group, Inc. and Argent BioPharma Limited (ASX/LSE: RGT) entered into an addendum to that certain exclusive global license agreement for CannEpil®, dated July 6, 2026. Filing
  19. Jul 21, 2026AgreementSplash Beverage Group, Inc. entered into amendments to certain settlement agreements, which the Company had previously entered into with three separate prior investors of the Company in February 2026. Filing
  20. Jul 16, 2026RulesChanged its bylaws or articles. Filing
  21. Jul 14, 2026AnnouncementShared information with investors. Filing
  22. Jul 13, 2026AgreementSplash Beverage Group, Inc. entered into a letter agreement with Decathlon Alpha IV, L.P., the lender under that certain Revenue Loan and Security Agreement dated December 24, 2020, as amended, pursuant to which the parties agreed that the Company may satisfy its outstanding obligations under the… Filing
  23. Jul 10, 2026SharesSold new shares outside a public offering. Filing
  24. Jul 9, 2026ListingThe Company received notice from NYSE Regulation that the NYSE has determined to accept the Company’s plan to regain compliance with the NYSE American’s shareholders’ equity requirement as outlined in Section 1003(a)(i), (ii), and (iii) of the Company Guide, which the Company submitted to the NYSE… Filing
  25. Jul 6, 2026AgreementSplash Beverage Group, Inc. entered into an Exclusive License Agreement with Argent Biopharma Limited pursuant to which the Company acquired the exclusive worldwide rights to the pharmaceutical product marketed under the brand name CannEpil®, comprising the Licensor’s proprietary compounded… Filing
  26. Jul 6, 2026AnnouncementShared information with investors. Filing
  27. Jun 26, 2026SharesSold new shares outside a public offering. Filing
  28. Jun 15, 2026AnnouncementShared information with investors. Filing
  29. Jun 12, 2026LeadershipThe Board of Directors of the Company appointed Michael Bondurant, as the Company’s Chief Operating Officer, effective immediately. Filing
  30. Jun 4, 2026SharesSold new shares outside a public offering. Filing
  31. Jun 3, 2026AnnouncementShared information with investors. Filing
  32. May 15, 2026LeadershipSplash Beverage Group, Inc. appointed Brady Cobb as the Company’s Interim Chief Executive Officer, effective immediately. Filing
  33. May 5, 2026ListingThe Company received notice from NYSE Regulation that the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined in Section 1003(a)(i), (ii), and (iii) of the Company Guide. Filing
  34. Apr 27, 2026LeadershipThe Board appointed Francis Knuettel II to serve on the Board, effective immediately. Filing
  35. Apr 24, 2026LeadershipOn April 21 and April 24, 2026, Justin Yorke and Robert Nistico, respectively, members of the Board of Directors of the Company, each notified the Company of his decision to resign from the Board, effective immediately . On April 23, 2026, the Company entered into a consulting agreement with Mr.… Filing
  36. Apr 21, 2026RulesChanged its bylaws or articles. Filing
  37. Mar 12, 2026AnnouncementShared information with investors. Filing
  38. Mar 5, 2026AnnouncementShared information with investors. Filing
  39. Feb 6, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. Filing
  40. Jan 30, 2026SharesSold new shares outside a public offering. Filing
  41. Jan 27, 2026AnnouncementShared information with investors. Filing
  42. Jan 26, 2026AgreementSplash Beverage Group, Inc., a Nevada corporation entered into an agreement with C/M Capital Master Fund, LP which Investor is the counterparty to that certain Securities Purchase Agreement dated September 19, 2025 establishing an equity line of credit facility between the Company and the Investor. Filing
  43. Dec 17, 2025LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. Filing
  44. Dec 10, 2025AgreementSplash Beverage Group, Inc. entered into agreements with holders of certain options to purchase a total of $600,000 of shares of the Company’s common stock, pursuant to which the parties agreed to terminate such options and in exchange the Company agreed to issue to the holders thereof a total of… Filing
  45. Nov 17, 2025SharesAmended an earlier report. Sold new shares outside a public offering. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Endovia Health Sciences financials

Famous investors that hold EDVA

1 of the 50 well-known investors we track reported holding EDVA in their latest 13F filing. The largest position is Ken Griffin's, worth $20K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026113,752$20K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named EDVA in the last 120 days.

FiledHolderFormStake
Oct 22, 2026C/M Capital Master Fund, LP13G7.2%
Oct 22, 2026C/M Capital Master Fund, LP13G7.2%

Questions about Endovia Health Sciences, Inc. (EDVA) stock

Are EDVA insiders buying or selling?

No EDVA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in EDVA?

As of Oct 30, 2026, 321,101 EDVA shares were sold short, 5.0% of the shares outstanding, up 51.3% from the report before. At the average daily volume of 598,840 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold EDVA?

1 of the 50 well-known investors we track reported EDVA in their latest 13F filing, including Ken Griffin. The largest position is worth $20K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.